Ratnakar Securities Pvt. Ltd.

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC

BSE2132.7567.35 (+3.26 %)

PREV CLOSE ( ) 2065.40

OPEN PRICE ( ) 2070.10

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 6612

TODAY'S LOW / HIGH ( )2056.60 2145.75

52 WK LOW / HIGH ( )1228 2649.95

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 13-11 1924

Management Info

R S Karnad - Chairman Bhushan Akshikar - Managing Director

Registered Office

Address Gsk House, Dr. Annie Besant Road,Worli,,
Mumbai,
Maharashtra-400030

Phone 022-24959595

Email in.investorquery@gsk.com

Website www.gsk-india.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE, MCX

NEWS

24Apr GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..

16Apr GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..

05Apr GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..

04Apr Glaxosmithkline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..

02Apr Glaxosmithkline Pharmaceuticals inform
In Compliance with Regulation 74(5) of SEBI (Depositories and Participan..

Financials

in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	454.900000000001	6077.5
Gross Profit	651.100000000001	8323.8
Operating Profit	2458.5	9009.3
Net Sales	8049.8	32163.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Divi's Lab (BSE) 4025.35 (4.81%)	M.Cap ( in Cr)106860.39
Sanofi India (BSE) 8278.10 (1.76%)	M.Cap ( in Cr)19064.98
Abbott India (BSE) 25864.85 (0.54%)	M.Cap ( in Cr)54961.00
Astrazeneca Pharma I (BSE) 5415.40 (2.18%)	M.Cap ( in Cr)13538.50
Ajanta Pharma (BSE) 2200.70 (2.94%)	M.Cap ( in Cr)27710.26

Shareholding Pattern

	PROMOTERS	75%
	MUTUAL FUNDS/UTI	4.51%
	FI/BANKS/INSURANCE	3.27%
	NON-INSTITUTION	13.62%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Quant Healthcare Fu...	3.39
Aditya Birla SL MNC...	3.02
Nippon India Pharma...	2.33
Quant Large & Mid C...	2.08
Quant Mid Cap Fund(G)	1.95
UTI Nifty Midcap 15...	1.83

attention investors
kyc
ipo
ibt trading

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES